Articles published by Novocure
 
   
    Novocure to Participate in Upcoming Investor Conferences
    
   August 25, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Reports Second Quarter 2023 Financial Results
    
   July 27, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
    
   
    Novocure to Report Second Quarter 2023 Financial Results
    
   July 03, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
    
   
    Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
    
   June 01, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
    
    
   
    Novocure to Report First Quarter 2023 Financial Results
    
   April 03, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Kristin Stafford Joins Novocure Board of Directors
    
   March 29, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
    
   March 16, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
    
   March 01, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
    
   
    Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
    
   February 23, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Allyson J. Ocean, M.D., Joins Novocure Board of Directors
    
   February 23, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
    
   February 15, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
    
   January 09, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
    
   January 05, 2023
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
    
   December 27, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
    
   November 29, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
    
   November 17, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
    
   November 15, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Secures CE Mark for New Array
    
   November 11, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
   
    Novocure Reports Third Quarter 2022 Financial Results
    
   October 27, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
    
    
    
   
    Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
    
   October 20, 2022
   From Novocure
   Via Business Wire
    Tickers
      NVCR
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
